Ribociclib Plus Letrozole in Patients with Hormone Receptor-positive, HER2-negative Advanced Breast Cancer with No Prior Endocrine Therapy: Subgroup Safety Analysis from The Phase 3b CompLEEment-1 Trial

BACKGROUND: The CDK4/6 inhibitor, ribociclib in combination with endocrine therapy significantly improved progression-free survival in the first line setting in post-menopausal patients with HR+/HER2− advanced breast cancer (ABC) in a pivotal phase 3, placebo-controlled trial (MONALEESA-2) and demon...

Descripción completa

Detalles Bibliográficos
Autores principales: Borstnar, Simona, Palacova, Marketa, Łacko, Aleksandra, Timcheva, Constanta, Gal-Yam, Einav Nili, Papazisis, Konstantinos, Beniak, Juraj, Kudela, Pavol, Rubovszky, Gábor
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Sciendo 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9122294/
https://www.ncbi.nlm.nih.gov/pubmed/35575587
http://dx.doi.org/10.2478/raon-2022-0020

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9122294/
https://www.ncbi.nlm.nih.gov/pubmed/35575587
http://dx.doi.org/10.2478/raon-2022-0020

Ejemplares similares